Alumis (ALMS) vs Kura Oncology (KURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Alumis (ALMS) has outperformed Kura Oncology (KURA) over the past year, gaining 58.1% versus a gain of 3.4%. Kura Oncology is the larger company by market cap ($943.0 million vs $926.8 million), about 1.0 times the size. Kura Oncology converts more of its revenue into profit, with a net margin of -412.9% versus -1011.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALMS | KURA |
|---|---|---|
| Share price | $7.16 | $10.60 |
| Market cap | $926.76M | $942.98M |
| 1-day change | +2.73% | +0.76% |
| YTD return | -26.64% | +2.02% |
| 1-year return | +58.06% | +3.41% |
| 5-year return | — | -41.18% |
| EPS (TTM) | $-3.86 | $-3.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $24.05M | $67.48M |
| Revenue growth (YoY) | — | +25.24% |
| Net income (latest FY) | $-243.32M | $-278.67M |
| Operating margin | -1886.92% | -449.94% |
| Net margin | -1011.75% | -412.95% |
| 52-week high | $31.35 | $13.90 |
| 52-week low | $4.28 | $7.36 |
| Distance from 52-week high | -77.16% | -23.74% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +348.74% | +200.47% |
| Average volume | 2.44M | 1.78M |
| Shares outstanding | 129.44M | 88.96M |
| Employees | 237 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALMS has outperformed KURA by 54.6 percentage points over the past year.
- Kura Oncology is more profitable, keeping -412.9 cents of every revenue dollar as net income versus -1011.7 cents for Alumis.
About Alumis
ALMS stock →Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 237 employees
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
ALMS vs KURA FAQ
Which is bigger, Alumis or Kura Oncology?
Kura Oncology (KURA) is larger, with a market capitalization of $942.98M compared with $926.76M for Alumis (ALMS).
Which stock has performed better over the past year, ALMS or KURA?
ALMS returned +58.06% over the past 12 months, compared with +3.41% for KURA (price return, excluding dividends). Past performance does not predict future results.
Are Alumis and Kura Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.